CAMK2N1 inhibits prostate cancer progression through androgen receptor-dependent signaling

Oncotarget

Volumn 5, Issue 21, 2014, Pages 10293-10306

  Wang, Tao ^a   Guo, Shuiming ^a   Liu, Zhuo ^a   Wu, Licheng ^a   Li, Mingchao ^a   Yang, Jun ^a   Chen, Ruibao ^a   Liu, Xiaming ^a   Xu, Hua ^a   Cai, Shaoxin ^a   Chen, Hui ^a   Li, Weiyong ^a   Xu, Shaohua ^d   Wang, Liang ^a   Hu, Zhiquan ^a   Zhuang, Qianyuan ^a   Wang, Liping ^b   Wu, Kongming ^a   Liu, Jihong ^a   Ye, Zhangqun ^a   Ji, Jun Yuan ^c   Wang, Chenguang ^e   Chen, Ke ^a   more..

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c TEXAS A M COLLEGE OF MEDICINE   (United States)

^d TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^e INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

Androgen receptor (AR); Camk2n1; prostate cancer; Tumor suppressor

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; PROTEIN CAMK2N1; PROTEIN KINASE B; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ANILIDE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; CAMK2N1 PROTEIN, HUMAN; NITRILE; ONCOPROTEIN; PROTEIN; SMALL INTERFERING RNA; TOLUENESULFONIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOREGULATION; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SIGNAL TRANSDUCTION; TRANSACTIVATION; CARCINOGENESIS; CARCINOMA; CELL GROWTH; DRUG RESISTANCE; FEEDBACK SYSTEM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; PROSTATE TUMOR; SURVIVAL ANALYSIS; TUMOR CELL CULTURE;

ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CARCINOGENESIS; CARCINOMA; CELL GROWTH PROCESSES; DRUG RESISTANCE; FEEDBACK, PHYSIOLOGICAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NITRILES; ONCOGENE PROTEIN V-AKT; PROSTATIC NEOPLASMS; PROTEINS; RECEPTORS, ANDROGEN; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TOSYL COMPOUNDS; TUMOR CELLS, CULTURED;

EID: 84916919321     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2511     Document Type: Article

References (35)

1. Alberti C. Prostate cancer progression and surrounding microenvironment. Int J Biol Markers. 2006, 21: 88-95.
2. So A, Gleave M, Hurtado-Col A, Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World J Urol. 2005, 23:1-9.
3. Devlin HL, Mudryj M. Progression of prostate cancer: multiple pathways to androgen independence. Cancer Lett. 2009, 274:177-86.
4. Mohla S, Stearns V, Sathyamoorthy N, Rosenfeld MG, Nelson P. The biology of hormone refractory breast and prostate cancer: An NCI workshop report. Cancer Biol Ther. 2009, 8:1975-85.
5. Bhandari MS, Petrylak DP, Hussain M. Clinical trials in metastatic prostate cancer-has there been real progress in the past decade. Eur J Cancer. 2005, 41:941-53.
6. Zhang J, Li N, Yu J, Zhang W, Cao X. Molecular cloning and characterization of a novel calcium/calmodulindependent protein kinase II inhibitor from human dendritic cells. Biochem Biophys Res Commun. 2001, 285:229-34.
7. Ling KH, Hewitt CA, Beissbarth T, Hyde L, Cheah PS, Smyth GK, Tan SS, Hahn CN, Thomas T, Thomas PQ, Scott HS. Spatiotemporal regulation of multiple overlapping sense and novel natural antisense transcripts at the Nrgn and Camk2n1 gene loci during mouse cerebral corticogenesis. Cereb Cortex. 2011, 21:683-97.
8. Tao Wang, Zhuo Liu, Shuiming Guo, Licheng Wu, Mingchao Li, Jun Yang, Ruibao Chen, Hua Xu, Shaoxin Cai, Hui Chen, Weiyong Li, Liang Wang, Zhiquan Hu, Qianyuan Zhuang, Shaohua Xu, Liping Wang, Jihong Liu, Zhangqun Ye, Jun-Yuan Ji, Chenguang Wang, and Ke Chen. The tumor suppressive role of CAMK2N1 in castration-resistant prostate cancer. Oncotarget. 2014, 5:3611-21.
9. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL. Integrative genomic profiling of human prostate cancer. Cancer cell. 2010,18:11-12.
10. Ju X, Ertel A, Casimiro MC, Yu Z, Meng H, McCue PA, Walters R, Fortina P, Lisanti MP, Pestell RG. Novel oncogene-induced metastatic prostate cancer cell lines define human prostate cancer progression signatures. Cancer Res. 2013, 73: 978-989.
11. DePrimo SE, Diehn M, Nelson JB, Reiter RE, Matese J, Fero M, Tibshirani R, Brown PO, Brooks JD. Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biol. 2002, 3:RESEARCH0032.
12. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, et al.: Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet. 2000, 24:227-235.
13. Urbanucci A, Marttila S, Jänne OA, Visakorpi T. Androgen receptor overexpression alters binding dynamics of the receptor to chromatin and chromatin structure. Prostate. 2012, 72: 1223-1232.
14. Takayama K, Horie-Inoue K, Ikeda K, Urano T, Murakami K, Hayashizaki Y, Ouchi Y, Inoue S. FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells. Biochem Biophys Res Commun. 2008, 374: 388-393.
15. Deb TB, Coticchia CM, Dickson RB. Calmodulinmediated activation of Akt regulates survival of c-Mycoverexpressing mouse mammary carcinoma cells. J Biol Chem. 2004, 279: 38903-38911.
16. Ha S, RuoffR, Kahoud N, Franke TF, Logan SK. Androgen receptor levels are upregulated by Akt in prostate cancer. Endocr Relat Cancer.2011, 18: 245-255.
17. Culig Z, Comuzzi B, Steiner H, Bartsch G., Hobisch, A. Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol. 2004, 92: 265-271.
18. Stan SD, Singh SV. Transcriptional repression and inhibition of nuclear translocation of androgen receptor by diallyl trisulfide in human prostate cancer cells. Clin Cancer Res. 2009, 15:4895-4903.
19. Snoek R, Cheng H, Margiotti K, Wafa LA, Wong CA, Wong EC, Fazli L, Nelson CC, Gleave ME, Rennie PS. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castrationresistant prostate tumors. Clin Cancer Res. 2009, 15:39-47.
20. Nacusi LP, Tindall DJ. Androgen receptor abnormalities in castration-recurrent prostate cancer. Expert Rev Endocrinol Metab. 2009, 4: 417-422.
21. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G., Yan DH, Hung MC. HER-2/neu promotes androgen independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res. 2000, 60: 6841-6845.
22. Manin M, Baron S, Goossens K, Beaudoin C, Jean C, Veyssiere G., Verhoeven G., Morel L. Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells. Biochem J. 2002, 366: 729-736.
23. Masiello D, Cheng S, Bubley G.J, Lu ML, Balk SP. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem. 2002; 277: 26321-26326.
24. Wang Y, Kreisberg JI, Bedolla RG, Mikhailova M, deVere White RW, Ghosh PM. A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodexresistant androgen receptor positive C4-2 prostate cancer cells. Oncogene. 2007, 26: 6061-6070.
25. Dehm SM, Tindall DJ. Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells. J Biol Chem. 2006, 281: 27882-93.
26. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G., Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 1994, 54: 5474-5478.
27. Gao H, Ouyang X, Banach-Petrosky WA, Gerald WL, Shen MM, Abate-Shen C. Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgenindependent prostate cancer. Proc Natl Acad Sci U S A. 2006, 103: 14477-14482.
28. Ellis L1, Ku SY, Ramakrishnan S, Lasorsa E, Azabdaftari G, Godoy A, Pili R. Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer. Oncotarget. 2013, 4:2225-36.
29. Li R, Wheeler T, Dai H, Frolov A, Thompson T, Ayala G. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am J Surg Pathol. 2004, 28: 928-934.
30. Lee YF, Shyr CR, Thin TH, Lin WJ, Chang C. Convergence of two repressors through heterodimer formation of androgen receptor and testicular orphan receptor-4: a unique signaling pathway in the steroid receptor superfamily. Proc Natl Acad Sci U S A. 1999, 96:14724-9.
31. Liu M, Ju X, Willmarth NE, Casimiro MC, Ojeifo J, Sakamaki T, Katiyar S, Jiao X, Popov VM, Yu Z, Wu K, Joyce D, Wang C, Pestell RG. Nuclear factor-kappaB enhances ErbB2-induced mammary tumorigenesis and neoangiogenesis in vivo. Am J Pathol. 2009, 174:1910-20.
32. Chen K, Wu K, Cai S, Zhang W, Zhou J, Wang J, Ertel A, Li Z, Rui H, Quong A, Lisanti MP, Tozeren A, Tanes C, Addya S, Gormley M, Wang C, McMahon SB, Pestell RG. Dachshund binds p53 to block the growth of lung adenocarcinoma cells. Cancer Res. 2013, 73:3262-74.
33. Chen K, Wu K, Gormley M, Ertel A, Wang J, Zhang W, Zhou J, Disante G., Li Z, Rui H, Quong, AA, McMahon SB, Deng H, Lisanti MP, Wang C., Pestell RG. Acetylation of the cell-fate factor dachshund determines p53 binding and signaling modules in breast cancer. Oncotarget. 2013, 4:923-35.
34. H HE, Sun Y. Ribosomal protein S27L is a direct p53 target that regulates apoptosis. Oncogen. 2007, 26: 2707-2716.
35. Wu K, Chen K, Wang C, Jiao X, Wang L, Zhou J, Wang J, Li Z, Addya S, Sorensen PH, Lisanti MP, Quong A, Ertel A, Pestell RG. Cell fate factor DACH1 represses YB-1-mediated oncogenic transcription and translation. Cancer Res. 2014, 74:829-39.